



INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/888,324
		Filing Date	June 22, 2001
		First Named Inventor	Juha Punnonen, et al.
		Group Art Unit	1644
		Examiner Name	Ilia I. Ouspenski
		Attorney Docket Number	0169.310US

U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
I.O.	A1	Number		Kind Code (if known)	
	A1	6,084,067		Freeman et al.	07/04/2000
	A2	6,071,716		Freeman et al.	06/06/2000
	A3	5,861,310		Freeman et al.	01/19/1999

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	A4	WO	95/03408		Dana-Farber Cancer Institute	02/02/1995		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS								
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s).						
	A5	DOTY, Raymond T. et al., "Subcellular localization of CD80 receptors is dependent on an intact cytoplasmic tail and is required for CD28-dependent T cell costimulation," <i>Journal of Immunology</i> 157:3270-3279 (1996)						
	A6	FREEMAN, Gordon J. et al., "Cloning of B7-2: A CTLA-4 counter-receptor that costimulates human T cell proliferation," <i>Science</i> 262:909-911 (November 1993)						
	A7	JENKINS, Marc K., "The ups and downs of T Cell costimulation," <i>Immunity</i> 1:443-446 (September 1994)						
	A8	KARANDIKAR, Nitin J. et al., "CTLA-4: A negative regulator of autoimmune disease," <i>J. Exp. Med.</i> , 184:783-788 (August 1996)						
	A9	LAZETIC, Sasha et al., "Chimeric co-stimulatory molecules that selectively act through CD28 or CTLA-4 on human t cells," <i>Journal of Biological Chemistry</i> 277(41):38660-38668 (2002)						
	A10	LINSLEY, Peter S. et al., "Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors," <i>Immunity</i> 1:793-801 (December 1994)						
	A11	LINSLEY, Peter S. et al., "Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation," <i>J. Exp. Med.</i> 173:721-730 (March 1991)						
	A12	PATTEN, Phillip et al., "Applications of DNA shuffling to pharmaceuticals and vaccines," <i>Current Opinion in Biotechnology</i> 8:724-733 (1997)						
I.O.	A13	PEACH, Robert J. et al., "Both extracellular immunoglobulin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28," <i>Journal of Biological Chemistry</i> 270(86):21181-21187 (1995)						

Examiner Signature	<i>Ilia Ouspenski</i>	Date Considered	05/26/2005
--------------------	-----------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



(Modified) PTO/SB/08A-B (10-96)
Approved for use through 10/31/99. OMB 0651-0031

Institute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	09/888,324
		Filing Date	June 22, 2001
		First Named Inventor	Juha Punnonen, <i>et al.</i>
		Group Art Unit	1644
		Examiner Name	Ilia I. Ouspenski
		Attorney Docket Number	0169.310US

\$-0.	A14	STEMMER, Willem P.C., "Searching sequence space: Using recombination to search more efficiently and thoroughly instead of making bigger combinatorial libraries," <i>Biotechnology</i> 13:549-553 (June 1995)	
I.O.	A15	STURMHOEFEL, Knut, "Potent activity of soluble B7-1gG fusion proteins in therapy of established tumors and as vaccine adjuvant," <i>Cancer Research</i> 59:4964-4972 (October 1999)	
\$-0.	A16	SWINIARSKI, Holly <i>et al.</i> , "Immune response enhancement by <i>in vivo</i> administration of B7.21g, a soluble costimulatory protein," <i>Clinical Immunology</i> 92(3):235-245 (1999)	

Examiner Signature	<i>Ilia Ouspenski</i>	Date Considered	05/26/2005
--------------------	-----------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.